绝经后雌激素受体富集/ERBB2阴性乳腺癌患者接受新辅助阿那曲唑、氟维司群或二者联合治疗的内分泌敏感疾病率:一项3期随机临床试验
该3期随机临床试验纳入绝经后临床II-III期、ER富集(Allred评分6-8或>66%)/ERBB2阴性乳腺癌患者,比较术前6个月阿那曲唑、氟维司群或二者联合的内分泌敏感疾病率(ESDR)。在1298例可评估患者中,三组ESDR分别为18.7%、22.8%和20.5%,含氟维司群方案未显著改善ESDR或第4周Ki67抑制;芳香化酶抑制剂仍是新辅助内分泌治疗的标准治疗。
要点
- 含氟维司群方案对比阿那曲唑单药未显著改善内分泌敏感疾病率。
- 第4周或第12周Ki67>10%的比例在阿那曲唑、氟维司群、联合组分别为25.1%、24.2%、15.7%。
- 探索性分析中,联合组在luminal B肿瘤的第4周Ki67抑制优于阿那曲唑单药。
核心结论
- 在该随机临床试验中,氟维司群或阿那曲唑联合氟维司群对比阿那曲唑单药均未显著改善ER富集/ERBB2阴性乳腺癌的6个月内分泌敏感疾病率。
- 芳香化酶抑制仍是新辅助内分泌治疗的标准治疗。
- 探索性分析中按PAM50亚型的内分泌治疗反应差异需进一步研究。
研究设计与样本
- 3期随机临床试验,评估含氟维司群各臂与阿那曲唑臂之间临床及关联结局的差异。
- 纳入绝经后临床II至III期、ER富集(Allred评分6-8或>66%)/ERBB2阴性乳腺癌女性。
- 患者术前接受阿那曲唑、氟维司群或二者联合治疗6个月。
- 2014年2月至2018年11月共入组1362例女性患者(平均[SD]年龄65.0[8.2]岁),可评估患者1298例。
- 所有分析基于2023年3月2日冻结的数据。
主要发现
- 可评估患者1298例中,阿那曲唑、氟维司群、联合组的内分泌敏感疾病率分别为18.7%(95%CI,15.1%-22.7%)、22.8%(95%CI,18.9%-27.1%)、20.5%(95%CI,16.8%-24.6%)。
- 对比阿那曲唑,含氟维司群方案均未显著改善内分泌敏感疾病率或第4周Ki67抑制。
- 第4周或第12周Ki67>10%的比例在阿那曲唑、氟维司群、联合组分别为25.1%、24.2%、15.7%。
- 因第4周或第12周Ki67>10%而转换为新辅助化疗后,167例中8例和167例中17例分别发生病理完全缓解/残留癌症负荷I类(15.0%;95%CI,9.9%-21.3%)。
- 753例(58%)基线活检RNA测序PAM50分型识别出394例luminal A、304例luminal B和55例非luminal肿瘤;联合组在luminal B肿瘤的第4周Ki67抑制大于阿那曲唑单药(中位[IQR],-90.4%[-95.2至-81.9%] vs -76.7%[-89.0至-55.6%];P<.001),在luminal A肿瘤则无此差异。
临床怎么用
- 芳香化酶抑制仍是新辅助内分泌治疗的标准治疗。
- 作者认为按PAM50亚型的内分泌治疗反应差异需进一步研究。
局限性
- 探索性分析中按PAM50亚型的内分泌治疗反应差异需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)-positive/ERBB2 (formerly HER2)-negative breast cancer. However, the combination has not been tested in early-stage disease. OBJECTIVE: To determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual disease (referred to as endocrine-sensitive disease) over anastrozole alone. DESIGN, SETTING, AND PARTICIPANTS: A phase 3 randomized clinical trial assessing differences in clinical and correlative outcomes between each of the fulvestrant-containing arms and the anastrozole arm. Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or >66%)/ERBB2-negative breast cancer were included. All analyses were based on data frozen on March 2, 2023. INTERVENTIONS: Patients received anastrozole, fulvestrant, or a combination for 6 months preoperatively. Tumor Ki67 was assessed at week 4 and optionally at week 12, and if greater than 10% at either time point, the patient switched to neoadjuvant chemotherapy or immediate surgery. MAIN OUTCOMES AND MEASURES: The primary outcome was the endocrine-sensitive disease rate (ESDR). A secondary outcome was the percentage change in Ki67 after 4 weeks of neoadjuvant endocrine therapy (NET) (week 4 Ki67 suppression). RESULTS: Between February 2014 and November 2018, 1362 female patients (mean [SD] age, 65.0 [8.2] years) were enrolled. Among the 1298 evaluable patients, ESDRs were 18.7% (95% CI, 15.1%-22.7%), 22.8% (95% CI, 18.9%-27.1%), and 20.5% (95% CI, 16.8%-24.6%) with anastrozole, fulvestrant, and A+F, respectively. Compared to anastrozole, neither fulvestrant-containing regimen significantly improved ESDR or week 4 Ki67 suppression. The rate of week 4 or week 12 Ki67 greater than 10% was 25.1%, 24.2%, and 15.7% with anastrozole, fulvestrant, and A+F, respectively. Pathologic complete response/residual cancer burden class I occurred in 8 of 167 patients and 17 of 167 patients, respectively (15.0%; 95% CI, 9.9%-21.3%), after switching to neoadjuvant chemotherapy due to week 4 or week 12 Ki67 greater than 10%. PAM50 subtyping derived from RNA sequencing of baseline biopsies available for 753 patients (58%) identified 394 luminal A, 304 luminal B, and 55 nonluminal tumors. A+F led to a greater week 4 Ki67 suppression than anastrozole alone in luminal B tumors (median [IQR], -90.4% [-95.2 to -81.9%] vs -76.7% [-89.0 to -55.6%]; P < .001), but not luminal A tumors. Thirty-six nonluminal tumors (65.5%) had a week 4 or week 12 Ki67 greater than 10%. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, neither fulvestrant nor A+F significantly improved the 6-month ESDR over anastrozole in ER-rich/ERBB2-negative breast cancer. Aromatase inhibition remains the standard-of-care NET. Differential NET response by PAM50 subtype in exploratory analyses warrants further investigation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01953588.
引用
- Ma CX, Suman VJ, Sanati S, et al. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38236590. doi:10.1001/jamaoncol.2023.6038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。